Effect of food on the antiviral activity of didanosine enteric-coated capsules: A pilot comparative study

HIV Medicine

Volumn 9, Issue 4, 2008, Pages 187-191

  Hernandez novoa B ^a   Antela, A ^a   Gutierrez C ^a   Perez Molina J A ^a   Perez Elias M J ^a   Dronda, F ^a   Moreno, A ^a   Casado, J L ^a   Page, C ^a   Pumares, M ^a   Galan J C ^a   Moreno, S ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Antiviral activity; Didanosine; Food effect

Indexed keywords

DIDANOSINE; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG COATING; DRUG EFFICACY; FEMALE; FOOD; FOOD DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONOTHERAPY; NONHUMAN; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ADMINISTRATION, ORAL; ADULT; CAPSULES; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DRUG ADMINISTRATION SCHEDULE; FASTING; FEMALE; FOOD; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL;

EID: 41549121085     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00543.x     Document Type: Article

References (23)

1. Perry CM, Noble S. Didanosine: An updated review of its use in HIV infection. Drugs 1999; 58: 1099-1135.
2. Damle BD, Yan JH, Behr D et al. Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads. J Clin Pharmacol 2002; 42: 419-427.
3. Damle BD, Kaul S, Behr D, Knupp C. Bioequivalence of two formulations of didanosine, encapsulated enteric-coated beads and buffered tablet, in healthy volunteers and HIV-infected subjects. J Clin Pharmacol 2002; 42: 791-797.
4. Damle B, Hess H, Kaul S, Knupp C. Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole. Biopharm Drug Dispos 2002; 23: 59-66.
5. Damle BD, Mummaneni V, Kaul S, Knupp C. Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin. Antimicrob Agents Chemother 2002; 46: 385-391.
6. La Porte C, Aarnoutse R, Koopmans P et al. Pharmacokinetics and food effect study of once daily (OD) indinavir (IDV)/ritonavir (RTV) with once-daily enteric coated (EC) didanosine (ddI). Fourth International Workshop on Clinical Pharmacology of HIV Therapy. Cannes, France, March 2003 [Abstract 3.2].
7. Stevens RC, Rodman JH, Yong FH, Carey V, Knupp CA, Frenkel LM. Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team. AIDS Res Hum Retroviruses 2000; 16: 415-421.
8. Girard P, Benech H, Gendron A et al. Food effect on the intracellular (IC) pharmacokinetics of dideoxyadenosine triphosphate (ddA-TP), the active metabolite of didanosine (ddI), in treated HIV-1-infected patients. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, December 2005 [Abstract H-1900].
9. Ahluwalia G, Cooney DA, Hartman NR et al. Anomalous accumulation and decay of 2′,3′-dideoxyadenosine-5′-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2′,3′-dideoxyinosine. Drug Metab Dispos 1993; 21: 369-376.
10. Lotterer E, Ruhnke M, Trautmann M, Beyer E, Bauer FE. Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal. Eur J Clin Pharmacol 1991; 40: 305-308.
11. Ruhnke M, Bauer FE, Seifert M, Traytmann M, Hille H, Koeppe P. Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. Antimicrob Agents Chemother 1993; 37: 2153-2158.
12. Nazareno LA, Holazo AA, Limjuco R et al. The effect of food on pharmacokinetics of zalcitabine in HIV-positive patients. Pharm Res 1995; 12: 1462-1465.
13. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990; 300: 230-235.
14. Molina JM, Marcelin AG, Pavie J et al. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: A randomized placebo-controlled trial. J Infect Dis 2005; 191: 840-847.
15. Louie M, Hogan C, Hurley A et al. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naïve chronically HIV-1-infected individuals. AIDS 2003; 17: 1151-1156.
16. Katzenstein DA, Winters M, Bubp J, Israeliski D, Winger E, Merigan TC. Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine. J Infect Dis 1994; 169: 416-419.
17. Yerly S, Kaiser L, Mermillod B, Baumberger C, Hirsche B, Perrin L. Response of HIV RNA to didanosine as a predictive marker of survival. AIDS 1995; 9: 159-163.
18. Yerly S, Kaiser L, Baumberger C, Hirschel B, Perrin LH. Early and prolonged decrease of viremia in HIV-1-infected patients treated with didanosine. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 358-364.
19. Gray G, Violari A, McIntyre J et al. Antiviral activity of nucleoside analogues during short-course monotherapy or dual therapy: Its role in preventing HIV infection in infants. J Acquir Immune Defic Syndr 2006; 42: 169-176.
20. Maggiolo F, Migliorino M, Maserati R et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir Ther 2001; 6: 249-253.
21. Reynes J, Denisi R, Massip P, Izopet J, Pellegrin I, Segondy M. Once-daily administration of didanosine in combination with stavudine in antiretroviral-naïve patients. The STADI Group. J Acquir Immune Defic Syndr 1999; 22: 103-105.
22. López Bernaldo de Quirós J, Moreno S, Jiménez-Oñate F, Clotet B, Rubio R, Hernandez Quero J. A cohort study of the food effect on virological failure and treatment discontinuation in patients on HAART containing didanosine enteric-coated capsules (FOODDIe Study). HIV Clin Trials 2006; 7: 155-162.
23. Berenguer J, Ribera E, Domingo P et al; GESIDA 39/03 Team. Didanosine, lamivudine and efavirenz vs. zidovudine, lamivudine and efavirenz, for initial treatment of HIV infection: Planned 24-week analysis of a prospective randomized non-inferiority clinical trial, GESIDA 39/03. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, February 2007 [Abstract J-108].